Vision and mission

Our vision is to prevent death and disability for millions of people worldwide suffering from serious cardiovascular diseases and to reduce the burden for individuals, families and society.

Our mission is to develop PP02 for the treatment of acute myocardial infarct (AMI) and additional acute and chronic ischemic diseases.

Read More

Acute Myocardial Infarct

Obstruction of the coronary blood flow during myocardial infarct limits oxygen supply to the heart. This promotes cardiac ischemia, cardiac dysfunction and ischemic heart disease. Ischemic heart disease feeds into a cardiometabolic disease acceleration loop. 

Ischemic heart disease is #1 global cause of death, disability and human suffering with costs of 11 bn$ in 2017 (US only) 

  • Fast therapeutic intervention to reperfuse tissue is essential for survival and positive prognosis
  • No pharmacological option for the rescue of heart function currently exists
  • There are more than 3 mio cases of AMI annually (1 mio in US only) and the estimated out of hospital mortality is 30-50%.
  • Currently, patients reaching the hospital for acute surgery foresee 10% mortality risk, 35% risk of secondary heart failure and 5-10% risk of 30-days readmission. 


6

WHAT MAKES US SPECIAL

Packaging & Storage

Turpis in eu mi bibendum neque egestas congue quisque. Eu non diam phasellus vestibulum lorem.

Warehouse Service

Turpis in eu mi bibendum neque egestas congue quisque. Eu non diam phasellus vestibulum lorem.

Delivery Services

Turpis in eu mi bibendum neque egestas congue quisque. Eu non diam phasellus vestibulum lorem.

service1
Investment planning
service2
Strategic approach
service3
Simple Business Solutions

The Epoqe Pharma Concept

Our PP compounds are analogs of a native peptide. PPs induce > 85% heart function recovery, > 55% perfusion defect recovery and increased survival rate in pre-clinical proof-of-concept studies in minipig (ischemia and rerperfusion) and rat (ischemia and reperfusion). 

The compounds have highly conserved biological actions among species. The solid rationale is based on well established biology, a well characterized receptor population and preferred actions, specifically in the heart tissue. 

circumvention

Increase blood supply to the infarcted area through direct vasodilatory effects.

Regeneration

Tissue regeneration through formation of new vasculature induces a biological bypass

Preservation

Heart muscle preservation through direct protection of the heart muscle.

Clinical expectations of PPs

We expect PPs to be safe based on long term clinical studies with the native peptide. 

Based on non-clinical studies we expect PPs to reduce the AMI patient mortality rate, reduce hospitalization, improve heart function and quality of life and reduce the risk of developing secondary heart failure

Importantly, the clinical efficacy is expected to be independent on the well established risk factors leading to the heart attack (e.g. age, diabetes, hypertension, dyslipideamia and coagulant status).


1+
Projects Completed
1+
Clients
1+
Employess
1+
Years of experience

WHAT PEOPLE SAY

Excepteur sint occaecat cupidatat non proident, suntin culpa qui officia deserunt mollit animid est laborum.Phasellus imperdiet lacinia nulla, malesuada semper nibh sodales quis, Duis viverra ipsum dictum.

testimonial1
Abella Smith Assistant Manager

Excepteur sint occaecat cupidatat non proident, suntin culpa qui officia deserunt mollit animid est laborum.Phasellus imperdiet lacinia nulla, malesuada semper nibh sodales quis, Duis viverra ipsum dictum.

testimonial2
Joel dawson Sales Manager

Excepteur sint occaecat cupidatat non proident, suntin culpa qui officia deserunt mollit animid est laborum.Phasellus imperdiet lacinia nulla, malesuada semper nibh sodales quis, Duis viverra ipsum dictum.

testimonial3
Misha Cross Manager

THE TEAM

anette
Anette Sams, PHD CSO, CEO & Co-founder
anette@epoqepharma.com 
jbu
Jens Bukrinski, phd CTO & Co-founder
jens@epoqepharma.com
Torgeir
Torgeir Vaage, PHD CFO


Thomas
Thomas Engstrøm, MD.  Advisor & Co-founder

Lasse
Lasse Nørregaard, Msc., Mba Business Developer
lasse@epoqepharma.com

Vivienne
Vivienne Mol, Phd  Business Developer
vivienne@epoqepharma.com

INVESTORS

The Epoqe Pharma concept has been supported by Innovation Fund Denmark

investor1

FOUNDERS

Anette Sams, PhD, Cand. Pharm. 

Former director and specialist in Novo Nordisk R&D. 

20+ years experience from target discovery, pharmacology, bioassays, and innovation leadership. Specialist in cardio-metabolic disease mechanisms. Has been involved in 40+ drug discovery projects with 3 drugs marketed. 

anette
Anette Sams, PHD Founder, CSO and CEO
sams@epoqe.dk

Mikael Thomsen, PhD, Cand. Pharm; Cand Scient. 

Drug development specialist (preclinical- and clinical pharmacology, toxicology, regulatory affairs).

 Experienced in biotech entrepreneurship (15+ years) and pharma industry (10+ years).

mikael
Mikael Thomsen, PHD Co-founder
  

Lars Edvinsson, Dr Med, Professor. 

World-recognized leading expert and pioneer within cerebral circulation, vascular innervation and receptor regulation with 30+ years of scientific excellence. Lars was awarded the prestigious Brain Prize 2021 for for his groundbreaking work. Chief Physisian at Lund  University and Centre Manager at Rigshospitalets Forskerpark.

lars
Lars Edvinsson, DR Founder
 

Jens Bukrinski, PhD, Cand. Lact. 

Founder of CMCAssist. Former Novo Nordisk & Novozymes Biopharma. 

CMC and regulatory expert with 20+ years’ experience from 30+ drug development projects with 8 drugs successfully approved. 

jbu
Jens Bukrinski, phd Co-founder, CTO
jens@epoqepharma.com